| First author [ref.] | Hayabuchi [4] | Yankelevitz [9] | Hasegawa [10] | Jennings [11] | Lindell [12] | Honda [13] | Mikita [14] | Sone [15] | Henschke [16] | Wilson [17] | Veronesi [18] |
| Year | 1983 | 2003 | 2000 | 2006 | 2007 | 2009 | 2012 | 2012 | 2012 | 2012 | 2012 |
| Origin of patients | Screening | Screening# | Screening | Mixed#,¶ | Screening | Clinical | Clinical+ | Mixed¶ | Screening | Screening | Screening |
| Imaging test | CR | CR | LDCT | LDCT | LDCT | LDCT | LDCT | LDCT | LDCT | LDCT | LDCT |
| Age years mean (range) | 65 | NR | 65 (33–89) | 72 (43–87)§ | 65 (53–79) | 66 (39–83) | 67 (46–86) | (33–80) | NR | NR | 58±5.6 |
| Cancers n | 107 | 114 | 82 | 393 | 68 | 51 | 34 | 87 | 111ƒ | 148 | 175 |
| VDT measured | 37 (35) | 87 (76) | 61 (74) | 149 (38) | 48 (71) | 51 (100) | 34 (100) | 45 (52) | 111ƒ (100) | 63 (43) | 120ƒ (69) |
| VDT days | |||||||||||
| Mean±sd | 452±381 | 518±1094 | 324 | 136 | |||||||
| Median (range) | 144–101 | 207 (26–∞)## | 258 (69–∞)##,¶¶, 121 (39–221) ++ | 357 (NR– 4263) | 240 (18–2555) | ||||||
| Cut-off days | >150 | >400 | >342§§ | >207ƒƒ | >400 | >700 | >400 | >365 | >400 | ||
| Slow-growing (measured/overall) | 29 (78/27) | 4 (5/3) | 31 (51/38) | 74 (50/19) | 13 (27/19) | 8 (23/23) | 3 (3/3) | 30 (48/20) | 31 (26/18) | ||
| VDT >400 days n (% overall) | 11 (10) | 4 (3) | 14### (17) | 21### (5) | 13 (19) | 16 (31) | 13 (38) | 39 (45) | 3 (3) | 31 (18) |
Data are presented as n, mean±sd or n (%), unless otherwise stated. VDT: volume doubling time; CR: chest radiography, LDCT: low-dose computed tomography; NR: not reported. #: stage I only; ¶: including screening and clinically detected patients; +: small solid nodules only; §: data presented as median (range); ƒ: nonprevalent cases only; ##: VDTs of regressing tumours would have negative value, but they are herewith expressed as an infinite value for clarity; ¶¶: adenocarcinoma only; ++: squamous carcinoma only; §§: geometric mean of VDTs; ƒƒ: median VDT; ###: only tumours showing no growth included in computation.